<DOC>
	<DOCNO>NCT02376972</DOCNO>
	<brief_summary>THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES ( 25 MG AND 100 MG ) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS</brief_summary>
	<brief_title>Efficacy Safety Study Rifaximin Vaginal Tablets Bacterial Vaginosis</brief_title>
	<detailed_description>THIS IS A PHASE 2B , RANDOMIZED , DOUBLE-BLIND , PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626 SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS . PRIMARY ENDPOINT : TO COMPARE THE EFFICACY OF TWO DOSES ( 25 MG AND 100 MG ) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS SECONDARY ENDPOINT : TO COMPARE THE EFFICACY OF TWO DOSES ( 25 MG AND 100 MG ) OF RIFAXIMIN VAGINAL TABLETS VERSUS METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Clinical diagnosis bacterial vaginosis Amsel 's criterion ( 4 4 fulfilled criterion ) : Off white ( milky gray ) , thin , homogeneous , adherent vaginal discharge pH &gt; 4.5 Positive `` whiff test '' Presence clue cell ≥20 % Bacteriological diagnosis bacterial vaginosis Gram stain Nugent score ≥ 4 ( patient may enrolled/randomized without result ) Postmenarchal , premenopausal female patient Nonpregnant ( negative urine pregnancy test Entry Visit/V1 ) breastfeed patient Patient age 18 50 year , inclusively Patient willing ask question personal medical health sexual history Patient capable willing conform study protocol Patient thoroughly inform aim study study procedure provide sign dated write informed consent form Patient agree abstain intercourse 5 day treatment period Patient agree also abstain intercourse 3 day schedule visit followup Patient agree abstain use intravaginal product ( i.e. , douche , feminine deodorant spray , tampon , spermicide , gel , foam , vaginal birth control ring diaphragm ) entire study period Patient agree use adequate method birth control duration study avoid pregnancy . Acceptable method include history bilateral tubal ligation , male partner vasectomy , hormonal contraceptive [ oral , patch , injectable implantable ( exclude intrauterine implantable device [ IUD ] , intrauterine system [ IUS ] vaginal ring ) , abstinence Patient agree abstain alcohol ingestion 5day treatment period 1 day afterward Virginity Patient infectious cause vulvovaginitis ( e.g. , candidiasis , Trichomonas vaginalis , Chlamydia trachomatis , Neisseria gonorrhoeae , active Herpes simplex lesion , Human Papilloma Virus lesion ) ; patient may enrolled/randomized without result ) Other vulvovaginal cervical condition , abnormality disorder confound interpretation clinical response ( include total hysterectomy ) Symptoms suggestive pelvic inflammatory disease Patient intra uterine device ( IUD ) , intrauterine system ( IUS ) , vaginal ring contraceptive method Patient severe hepatic insufficiency ( Child C ) Patient severe cardiac insufficiency ( NYHA New York Heart Association class 3 4 ) Patient evaluate , include colposcopy cervical biopsy , treat study period , abnormal Pap test cervical carcinoma . To note Pap test perform baseline , result know randomization visit : patient may enrol without result Any condition circumstance would prevent completion study interfere analysis study result , include history drug alcohol abuse , mental illness noncompliance treatment visit , immunological ( include HIV infection ) , hematological neoplastic disease ( include cervical neoplastic disease ) Cervical cryotherapy , loop electrosurgical excision ( LEEP ) , cervical laser , ablative excisional cervical procedure within last 3 month Vaginal laser within last 3 month Patient clinically relevant pathological laboratory value Known hypersensitivity rifaximin Known hypersensitivity excipients present rifaximin , placebo metronidazole formulation Known hypersensitivity metronidazole , either orally topically administer , form parabens Concurrent anticoagulant therapy coumadin warfarin Menstruating anticipate menstruation/withdrawal bleed Entry Visit/V1 drug administration Patient receive antifungal antimicrobial therapy ( systemic intravaginal ) within 14 day randomization Patient participate another clinical trial take investigational drug within last 4 week prior screen Patient take disulfuram within last 14 day Withdrawal inform consent Patient previously randomize study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>